EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines

Journal of Oral Pathology and Medicine

Volumn 42, Issue 1, 2013, Pages 26-36

  Jedlinski, Adam ^a   Ansell, Anna ^b   Johansson, Ann Charlotte ^b   Roberg, Karin ^a,b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Chemoradiotherapy; EGFR; Epiregulin; Erbitux ; HB EGF; SCCHN; TGF ; Treatment response

Indexed keywords

AMPHIREGULIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; MESSENGER RNA; PROTEIN KINASE B;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GINGIVA TUMOR; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LARYNX CANCER; MALE; MAXILLA SINUS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TONGUE CANCER; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMORADIOTHERAPY; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; GENE DOSAGE; HEAD AND NECK NEOPLASMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; STATISTICS, NONPARAMETRIC;

EID: 84871939282     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2012.01177.x     Document Type: Article

References (37)

1. Shah JP, Lydiatt W. Treatment of cancer of the head and neck. CA Cancer J Clin 1995; 45: 352-68.
2. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007; 4: 156-71.
3. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.
4. Loeffler-Ragg J, Schwentner I, Sprinzl GM, et al. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs 2008; 17: 1517-31.
5. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
6. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24: 1072-8.
7. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218: 460-6.
8. P OC, Rhys-Evans P, Eccles S. Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells. Int J Cancer 2000; 88: 759-65.
9. Du B, Altorki NK, Kopelovich L, et al. Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: evidence of a cyclic AMP-responsive element binding protein-dependent mechanism. Cancer Res 2005; 65: 5982-8.
10. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009; 27: 5068-74.
11. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7.
12. Amornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004; 10: 4029-37.
13. Roberg K, Ceder R, Farnebo L, et al. Multiple genotypic aberrances associate to terminal differentiation-deficiency of an oral squamous cell carcinoma in serum-free culture. Differentiation 2008; 76: 868-80.
14. Nilsson JA, Hedberg JJ, Vondracek M, et al. Alcohol dehydrogenase 3 transcription associates with proliferation of human oral keratinocytes. Cell Mol Life Sci 2004; 61: 610-7.
15. Leutenegger CM, Mislin CN, Sigrist B, et al. Quantitative real-time PCR for the measurement of feline cytokine mRNA. Vet Immunol Immunopathol 1999; 71: 291-305.
16. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
17. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-84.
18. Ongkeko WM, Altuna X, Weisman RA, et al. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 2005; 124: 71-6.
19. Bei R, Budillon A, Masuelli L, et al. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 2004; 204: 317-25.
20. Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 11-20.
21. Eriksen JG, Steiniche T, Askaa J, et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004; 58: 561-6.
22. Farnebo L, Jedlinski A, Ansell A, et al. Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. Int J Mol Med 2009; 24: 549-56.
23. Mandic R, Rodgarkia-Dara CJ, Krohn V, et al. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor. Anticancer Res 2009; 29: 1181-7.
24. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
25. Kiaris H, Spandidos DA, Jones AS, et al. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 1995; 72: 123-8.
26. Erjala K, Sundvall M, Junttila TT, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006; 12: 4103-11.
27. Yamatodani T, Ekblad L, Kjellen E, et al. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 2009; 135: 395-402.
28. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-5.
29. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-86.
30. Pernas FG, Allen CT, Winters ME, et al. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 2009; 15: 2361-72.
31. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004; 13: 3029-43.
32. Hatakeyama H, Cheng H, Wirth P, et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS ONE 2010; 5: e12702.
33. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-73.
34. Lammering G, Hewit TH, Holmes M, et al. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res 2004; 10: 6732-43.
35. Lammering G, Valerie K, Lin PS, et al. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 2004; 72: 267-73.
36. Burtness B. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck. J Clin Oncol 2005; 23: 5440-2.
37. Yano S, Yamada T, Takeuchi S, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011; 6: 2011-7.